50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to develop and commercialize novel therapeutics to treat diseases of the eye, with an initial focus on diseases of the back of the eye.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-2191% match
“Our mission is to develop disease-modifying, regenerative therapies to restore vision to millions of patients.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-01-2476% match
“Our mission is to discover and develop novel therapeutics to address significant medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-03-1974% match
“Our mission is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-1474% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2473% match
“Our mission is to develop and commercialize novel and best-in-class therapeutics to address unmet medical needs in the emerging otology market.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-03-1873% match
“Our mission is to discover and develop novel therapeutic drugs to treat diseases and disorders for which there are no adequate therapies or for which a new drug would represent a significant advancement over the current therapy.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-1473% match
“Our mission is to improve the vision health and quality of life of patients around the world by developing medicines that save sight and improve eye care for patients.”In use 2025 – now·1 sighting·SEC Form 20-F, filed 2025-03-1173% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2273% match
“Our mission is to develop, manufacture and distribute worldwide visual implants and other ophthalmic products that improve the vision of patients with cataracts, refractive conditions and glaucoma.”In use 2005 – now·1 sighting·SEC Form 10-K/A, filed 2005-04-2172% match
“Our mission is to bring new medicines to patients suffering from blinding diseases, and we think you can play a key role in helping make our vision a reality.”In use 2014 – now·1 sighting·SEC Form S-1, filed 2014-06-3072% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1472% match
“Our mission is to develop novel therapeutics to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-03-2872% match
“Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0772% match
“Our mission is to develop first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other rare disorders.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2772% match
“Our mission is to expand our portfolio into a wide range of muscle diseases and become a leader in this area by advancing life-transforming therapeutics for patients with serious muscle diseases.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0471% match
“Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2571% match
“Our mission is to build an ophthalmology-focused biopharmaceutical company that capitalizes on the gaps that we believe increasingly exist in the ophthalmology sector between single product companies and large, multi-product pharmaceutical companies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-0671% match
“Our mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-2371% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0171% match
“Our mission is to extend and enhance the lives of patients by discovering, developing, and commercializing novel pharmaceutical products for treating severe medical conditions.”In use 2007 – now·1 sighting·SEC Form 424B4, filed 2007-02-0771% match
“Our mission is to develop, register and commercialize safe and effective drugs, with novel mechanisms of action, to meet the major unmet medical needs of patients on a global basis.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-1570% match
“Our mission is to commercialize innovative drug candidates with novel mechanisms of action as well as intellectual property generated from our research activities for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-07-1670% match
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1170% match
“Our mission is to create long-term stockholder value by acquiring, developing and commercializing innovative products for the treatment of a variety of human diseases that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment.”In use 2014 – now·1 sighting·SEC Form 10-K, filed 2014-03-1170% match
“Our mission is to develop and commercialize innovative medicines that change the course of the disease in patients who suffer from age-related brain disorders.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1370% match
“Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2670% match
“Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2170% match
“Our mission is to maintain and restore sight in patients by building the leading vertically integrated retinal gene therapy company.”In use 2017 – now·1 sighting·SEC Form 424B4, filed 2017-09-2870% match
“Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2670% match
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1070% match
“Our mission is to enrich clinical practice and the patient/consumer experience by developing and commercializing topically applied products which offer the benefits of our advanced bioactive small molecule peptide technology.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-2770% match
“Our mission is to develop and commercialize proprietary therapeutic drug products that treat rare and orphan diseases, particularly for those diseases where no approved treatment currently exists.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2670% match
“Our mission is to discover and develop best- and first-in-class medicines for a broad range of difficult-to-treat diseases in collaboration with our partners.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-0870% match
“Our mission is to develop next generation cell and gene therapeutics with the capacity to cure.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0770% match
“Our mission is to develop and commercialize innovative antibody-based therapeutics for the treatment of solid tumors that are designed to bind depending on the physical and chemical properties of tumors and their microenvironment.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-04-2970% match
“Our mission is to leverage unique insights into protein motion to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of small molecule therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2670% match
“Our mission is to develop treatments for serious diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2270% match
“Our mission is to become a leading pharmaceutical company by pioneering Bicycle molecules as a novel therapeutic modality to treat diseases that are inadequately addressed with existing treatment modalities.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1770% match
“Our mission is to improve the lives of patients by accelerating the development of our customers’ drugs and devices through innovative solutions.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-2770% match
“Our mission is to discover and develop a pipeline of EPBs to treat a broad range of diseases and disorders, with an initial focus on cancers with a high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-04-2669% match
“Our mission is to discover or acquire novel therapeutic product candidates targeting unmet medical needs in attractive specialty markets.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-03-1569% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0269% match
“Our mission is to develop therapeutic drugs designed to treat neurodegenerative diseases, currently focusing on Parkinsonian and other movement disorders.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-08-2869% match
“Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2669% match
“Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-05-0169% match
“Our mission is to improve the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of novel protein degraders.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2469% match
“Our mission is to develop innovative therapies to address areas of high unmet medical need, initially in RASopathies for NF1.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3069% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0169% match
“Our mission is to develop and commercialize technologies to treat diseases of the heart, with an initial focus on the Holly Graft System for use in CABG.”In use 2004 – now·1 sighting·SEC Form 424B4, filed 2004-12-0869% match
Showing 1–50 of 50